• Je něco špatně v tomto záznamu ?

A novel rapamycin cream formulation improves facial angiofibromas associated with tuberous sclerosis complex: a double-blind randomized placebo-controlled trial

P. Aitken, I. Stanescu, L. Boddington, C. Mahon, A. Fogarasi, YH. Liao, M. Ivars, E. Moreno-Artero, D. Trauner, ST. DeRoos, J. Jancic, M. Nikolic, P. Balážová, HN. Price, K. Hadzsiev, K. Riney, S. Stapleton, MM. Tollefson, D. Bauer, B. Pinková,...

. 2023 ; 189 (5) : 520-530. [pub] 2023Oct25

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu randomizované kontrolované studie, multicentrická studie, klinické zkoušky, fáze II, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24000991

Grantová podpora
Dermatology Specialties Limited Partnership (DSLP)

BACKGROUND: Facial angiofibromas (FAs) are a major feature of tuberous sclerosis complex (TSC). Topical rapamycin can successfully treat FAs. A new stabilized cream formulation that protects rapamycin from oxidation has been developed in 0.5% and 1% concentrations. OBJECTIVES: To assess the efficacy and safety of a novel, stabilized topical rapamycin cream formulation. METHODS: This multicentre double-blind randomized placebo-controlled dose-response phase II/III study with a parallel design included participants aged 6-65 years with FAs of mild or moderate severity according to the Investigator's Global Assessment (IGA) scale. Participants were randomized to one of three treatment arms: topical rapamycin 0.5%, topical rapamycin 1% or placebo. Treatment was applied once daily for 26 weeks. Safety and efficacy measures were assessed at days 14, 56, 98, 140 and 182. The primary endpoint was the percentage of participants achieving IGA scores of 'clear' or 'almost clear' after 26 weeks of treatment. Secondary measures included Facial Angiofibroma Severity Index (FASI) and participant- and clinician-reported percentage-based improvement. Safety measures included the incidence of treatment-emergent adverse events and blood rapamycin concentration changes over time. RESULTS: Participants (n = 107) were randomized to receive either rapamycin 1% (n = 33), rapamycin 0.5% (n = 36) or placebo (n = 38). All treated participants were included in the final analysis. The percentage of participants with a two-grade IGA improvement was greater in the rapamycin 0.5% treatment group (11%) and rapamycin 1% group (9%) than in the placebo group (5%). However, this was not statistically significant [rapamycin 0.5%: odds ratio (OR) 1.71, 95% confidence interval (CI) 0.36-8.18 (P = 0.50); rapamycin 1%: OR 1.68, 95% CI 0.33-8.40 (P = 0.53)]. There was a statistically significant difference in the proportion of participants treated with rapamycin cream that achieved at least a one-grade improvement in IGA [rapamycin 0.5%: 56% (OR 4.73, 95% CI 1.59-14.10; P = 0.005); rapamycin 1%: 61% (OR 5.14, 95% CI 1.70-15.57; P = 0.004); placebo: 24%]. Skin adverse reactions were more common in patients following rapamycin application (64%) vs. placebo (29%). CONCLUSIONS: Both rapamycin cream formulations (0.5% and 1%) were well tolerated, and either strength could lead to clinical benefit in the treatment of FA.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24000991
003      
CZ-PrNML
005      
20240213093538.0
007      
ta
008      
240109s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/bjd/ljad243 $2 doi
035    __
$a (PubMed)37463422
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Aitken, Phillip $u AFT Pharmaceuticals Ltd, Auckland, New Zealand $1 https://orcid.org/000000033934265X
245    12
$a A novel rapamycin cream formulation improves facial angiofibromas associated with tuberous sclerosis complex: a double-blind randomized placebo-controlled trial / $c P. Aitken, I. Stanescu, L. Boddington, C. Mahon, A. Fogarasi, YH. Liao, M. Ivars, E. Moreno-Artero, D. Trauner, ST. DeRoos, J. Jancic, M. Nikolic, P. Balážová, HN. Price, K. Hadzsiev, K. Riney, S. Stapleton, MM. Tollefson, D. Bauer, B. Pinková, H. Atkinson
520    9_
$a BACKGROUND: Facial angiofibromas (FAs) are a major feature of tuberous sclerosis complex (TSC). Topical rapamycin can successfully treat FAs. A new stabilized cream formulation that protects rapamycin from oxidation has been developed in 0.5% and 1% concentrations. OBJECTIVES: To assess the efficacy and safety of a novel, stabilized topical rapamycin cream formulation. METHODS: This multicentre double-blind randomized placebo-controlled dose-response phase II/III study with a parallel design included participants aged 6-65 years with FAs of mild or moderate severity according to the Investigator's Global Assessment (IGA) scale. Participants were randomized to one of three treatment arms: topical rapamycin 0.5%, topical rapamycin 1% or placebo. Treatment was applied once daily for 26 weeks. Safety and efficacy measures were assessed at days 14, 56, 98, 140 and 182. The primary endpoint was the percentage of participants achieving IGA scores of 'clear' or 'almost clear' after 26 weeks of treatment. Secondary measures included Facial Angiofibroma Severity Index (FASI) and participant- and clinician-reported percentage-based improvement. Safety measures included the incidence of treatment-emergent adverse events and blood rapamycin concentration changes over time. RESULTS: Participants (n = 107) were randomized to receive either rapamycin 1% (n = 33), rapamycin 0.5% (n = 36) or placebo (n = 38). All treated participants were included in the final analysis. The percentage of participants with a two-grade IGA improvement was greater in the rapamycin 0.5% treatment group (11%) and rapamycin 1% group (9%) than in the placebo group (5%). However, this was not statistically significant [rapamycin 0.5%: odds ratio (OR) 1.71, 95% confidence interval (CI) 0.36-8.18 (P = 0.50); rapamycin 1%: OR 1.68, 95% CI 0.33-8.40 (P = 0.53)]. There was a statistically significant difference in the proportion of participants treated with rapamycin cream that achieved at least a one-grade improvement in IGA [rapamycin 0.5%: 56% (OR 4.73, 95% CI 1.59-14.10; P = 0.005); rapamycin 1%: 61% (OR 5.14, 95% CI 1.70-15.57; P = 0.004); placebo: 24%]. Skin adverse reactions were more common in patients following rapamycin application (64%) vs. placebo (29%). CONCLUSIONS: Both rapamycin cream formulations (0.5% and 1%) were well tolerated, and either strength could lead to clinical benefit in the treatment of FA.
650    _2
$a lidé $7 D006801
650    _2
$a sirolimus $7 D020123
650    12
$a angiofibrom $x komplikace $x farmakoterapie $7 D018322
650    12
$a tuberózní skleróza $x komplikace $x farmakoterapie $7 D014402
650    _2
$a imunosupresiva $x škodlivé účinky $7 D007166
650    _2
$a emoliencia $x terapeutické užití $7 D004643
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a imunoglobulin A $7 D007070
650    _2
$a výsledek terapie $7 D016896
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a multicentrická studie $7 D016448
655    _2
$a klinické zkoušky, fáze II $7 D017427
655    _2
$a časopisecké články $7 D016428
700    1_
$a Stanescu, Ioana $u AFT Pharmaceuticals Ltd, Auckland, New Zealand $1 https://orcid.org/0000000267247185
700    1_
$a Boddington, Laura $u AFT Pharmaceuticals Ltd, Auckland, New Zealand $1 https://orcid.org/0000000177082401
700    1_
$a Mahon, Caroline $u Dermatology Department, Christchurch Hospital, Christchurch, New Zealand
700    1_
$a Fogarasi, Andras $u Bethesda Children's Hospital, Budapest, Hungary
700    1_
$a Liao, Yi-Hua $u Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan $1 https://orcid.org/0000000244343780
700    1_
$a Ivars, Marta $u Dermatology Department, Clínica Universidad de Navarra, Madrid, Spain $1 https://orcid.org/0000000325003200
700    1_
$a Moreno-Artero, Ester $u Dermatology Department, Clínica Universidad de Navarra, Madrid, Spain $1 https://orcid.org/0000000312812009
700    1_
$a Trauner, Doris $u University of California San Diego Health Sciences, Department of Neurosciences, San Diego, CA, USA
700    1_
$a DeRoos, Steven T $u Helen DeVos Children's Hospital, Grand Rapids, MI, USA
700    1_
$a Jancic, Jasna $u Faculty of Medicine, University of Belgrade, Belgrade, Serbia $u Clinic of Neurology and Psychiatry for Children and Youth, Belgrade, Serbia $1 https://orcid.org/0000000229350798
700    1_
$a Nikolic, Milos $u University of Belgrade School of Medicine, Department of Dermatovenereology, University Clinical Center of Serbia, Belgrade, Serbia $1 https://orcid.org/0000000239265394
700    1_
$a Balážová, Patrícia $u Department of Pediatric Neurology, Faculty of Medicine, Comenius University, National Institute of Children's Diseases, Bratislava, Slovakia
700    1_
$a Price, Harper N $u Division of Dermatology, Phoenix Children's Hospital, Phoenix, AZ, USA $1 https://orcid.org/0000000284732369
700    1_
$a Hadzsiev, Kinga $u Department of Medical Genetics, Medical School, University of Pécs, Pécs, Hungary $1 https://orcid.org/0000000323031670
700    1_
$a Riney, Kate $u Neurosciences Unit, Queensland Children's Hospital, South Brisbane, QLD, Australia $u Faculty of Medicine, University of Queensland, St Lucia, QLD, Australia
700    1_
$a Stapleton, Stacie $u Johns Hopkins All Children's Hospital, St Petersburg, FL, USA
700    1_
$a Tollefson, Megha M $u Departments of Dermatology and Pediatrics, Mayo Clinic and Mayo Clinic Children's Center, MN, USA
700    1_
$a Bauer, Derek $u University of Virginia, Charlottesville, VA, USA
700    1_
$a Pinková, Blanka $u Department of Paediatric Dermatology, Faculty Hospital, Brno, Czech Republic
700    1_
$a Atkinson, Hartley $u AFT Pharmaceuticals Ltd, Auckland, New Zealand
773    0_
$w MED00009371 $t British journal of dermatology $x 1365-2133 $g Roč. 189, č. 5 (2023), s. 520-530
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37463422 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240109 $b ABA008
991    __
$a 20240213093535 $b ABA008
999    __
$a ok $b bmc $g 2049548 $s 1210685
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 189 $c 5 $d 520-530 $e 2023Oct25 $i 1365-2133 $m British journal of dermatology $n Br J Dermatol $x MED00009371
GRA    __
$p Dermatology Specialties Limited Partnership (DSLP)
LZP    __
$a Pubmed-20240109

Najít záznam

Citační ukazatele

Možnosti archivace